Month: August 2024

TP53 mutations not only profoundly affect the progression trajectory of chronic lymphocytic leukemia (CLL), but are also directly associated with poor prognosis, becoming an important factor that cannot be ignored when assessing disease severity and formulating personalized treatment strategies. At the highly anticipated 29th Annual Congress of the European Hematology Association (EHA 2024), Dr. Consuelo Bertossi from the Department of Internal Medicine III at the University of Ulm in Germany, through an exciting oral presentation, deeply analyzed the "The Landscape of TP53 Mutations and Their Prognostic Impact in Chronic Lymphocytic Leukemia (S101)", providing valuable data and insights for the attendees, which has important guiding value for clinical practice and scientific research exploration. To further discuss this cutting-edge topic, "Oncology Frontier-Hematology Frontier" specially invited Dr. Consuelo Bertossi for an interview on the spot, sharing the impact of TP53 mutations on survival rates, the efficacy of targeted drugs, and future research directions.

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Li Bao from Beijing Jishuitan Hospital for an exclusive interview to discuss advancements in the field and share academic insights.

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To capture the conference's dynamics and facilitate in-depth exchange, Oncology Frontier - Hematology Frontier invited Dr. Kai Hu from Beijing GoBroad Hospital for an exclusive interview. He provided insightful explanations on the topic of "The Application of Immunotherapy in Lymphoma/Myeloma."

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. At this conference, Dr. Lin Fu from the Department of Hematology at Beijing Tiantan Hospital delivered an insightful presentation on the "Advances in Diagnosis and Treatment of Primary Central Nervous System Lymphoma (PCNSL)." To capture the conference's dynamics and facilitate in-depth exchange, Oncology Frontier - Hematology Frontier conducted an exclusive interview with Dr. Lin Fu. The following is a summary for readers' reference.

Acute promyelocytic leukemia (APL) is a highly aggressive hematological disease, and its treatment has long been a challenge in the field. Chinese scholars have contributed significantly to global APL treatment with the introduction of the arsenic trioxide (ATO) regimen. Since the publication of the APL0406 study in NEJM in 2013, the combination of all-trans retinoic acid (ATRA) and ATO has replaced ATRA combined with chemotherapy as the standard treatment for low- and intermediate-risk APL patients. However, whether this regimen is suitable for high-risk APL patients remains undetermined due to a lack of randomized controlled trials. At the 29th Annual Meeting of the European Hematology Association (EHA 2024) held from June 13-16, 2024, Dr. Uwe Platzbecker from the Leipzig University in Germany presented key findings from the APOLLO study. This study demonstrated that the combination of ATO and ATRA offers a new treatment strategy for high-risk APL patients, providing valuable insights into the current state of APL treatment and guiding future research directions and clinical practices. Oncology Frontier - Hematology Frontier invited Professor Platzbecker to share the important discoveries and clinical significance of the APOLLO study.

On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was grandly held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Xiaoyan Ke from the Peking University Third Hospital/Beijing GoBroad Hospital for an exclusive interview to discuss advancements in the field and share academic insights.